Investigating how inflammation affects blood vessel health in e-cigarette users
Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
This study is testing how inflammation affects blood vessel health in young adults who use e-cigarettes compared to those who don’t, while also seeing if an anti-inflammatory medication can help improve their vascular function.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years to 24 Years |
| Sex | All |
| Sponsor | University of Iowa Academic / other |
| Locations | 2 sites (Iowa City, Iowa and 1 other locations) |
| Trial ID | NCT06489249 on ClinicalTrials.gov |
What this trial studies
This study examines the role of inflammation in the vascular health of individuals who use e-cigarettes. It focuses on young adults aged 18 to 24, comparing those with a history of e-cigarette use to those who have never used them. Participants will receive either a placebo or Salsalate, an anti-inflammatory medication, to assess its effects on endothelial function. The study aims to provide insights into the cardiovascular risks associated with e-cigarette use.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 18-24, either current e-cigarette users with at least six months of use or non-users.
Not a fit: Patients with a history of tobacco cigarette use or existing cardiovascular or metabolic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help clarify the cardiovascular risks of e-cigarette use and inform safer public health policies.
How similar studies have performed: While there is limited research specifically on e-cigarettes, studies on smoking and inflammation have shown significant findings, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 - 24 years of age * no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use). Exclusion Criteria: * tobacco cigarette use (current or history of) * use of stimulant drugs * skin diseases * cardiovascular disease * diagnosed or suspected hepatic or metabolic disease including diabetes * statin or other cholesterol-lowering medication * antihypertensive medication * current pregnancy or breastfeeding * blood pressure greater than or equal to 140mmHg systolic and/or greater than or equal to 90mmHg diastolic * allergy to materials used during the experiment * known allergies to salsalate or other study drugs
Where this trial is running
Iowa City, Iowa and 1 other locations
- Iowa Bioscience Innovation Facility — Iowa City, Iowa, United States (Recruiting)
- University of Iowa — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Study coordinator: Anna Stanhewicz, PhD
- Email: anna-stanhewicz@uiowa.edu
- Phone: 3194671732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.